Drug Profile
Cobolimab - AnaptysBio/GSK
Alternative Names: Anti-TIM-3-antibody-GSK; GSK-4069889; TSR 022; WBP 296ALatest Information Update: 22 Apr 2024
Price :
$50
*
At a glance
- Originator AnaptysBio
- Developer AnaptysBio; GSK; TESARO; University of Pittsburgh
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; HAVCR2 protein inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Non-small cell lung cancer
- Phase II Cervical cancer; Liver cancer; Malignant melanoma
- Phase I Solid tumours
Most Recent Events
- 12 Apr 2024 AnaptysBio has patent protection for cobolimab in various countries, as of December 2023 (AnaptysBio, Form 10-K)
- 12 Apr 2024 AnaptysBio has patents pending for cobolimab in various countries, as of December 2023 (AnaptysBio, Form 10-K)
- 11 Mar 2024 Phase-II clinical trials in Cervical cancer (Combination therapy, Metastatic disease, Second-line therapy or greater, Late-stage disease) in USA (IV) (NCT06238635)